HDGFL2 and malaria: The bead-based platform using the xMAP technology has been applied for the development of two noncommercial multiplex malaria antigen assays targeting HRP2, PanLDH, PfLDH, PvLDH and pAldo in whole blood, plasma, and dried blood spot (DBS) [11–13].